EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis

Phil McEwan, Peter D Gabb, Jason A Davis, Juan Jose Garcia Sanchez, C David Sjöström, Salvatore Barone, Pavlos Kashioulis, Mario Ouwens, Syd Cassimaty, Ricardo Correa-Rotter, Peter Rossing iD, David C Wheeler und 1 weitere

Nephrology Dialysis Transplantation · 2024

DOI: 10.1093/ndt/gfae106 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nephrology Dialysis Transplantation, 2024. Verfasst von Phil McEwan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics and Outcomes Research Ltd, Cardiff, UK. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic kidney disease (CKD) presents a significant clinical and economic burden to healthcare systems worldwide, which increases considerably with progression towards kidney failure. The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial demonstrated that patients with or without type 2 diabetes who were treated with dapagliflozin experienced slower progression of CKD versus those receiving placebo. Understanding the effect of long-term treatment with dapagliflozin on the timing of kidney failure beyond trial follow-up can assist informed decision-making by healthcare providers and patients. The study objective was therefore to extrapolate the outcome-based clinical benefits of treatment with dapagliflozin in patients with CKD via a time-to-event analysis using trial data.

Methods

Patient-level data from the DAPA-CKD trial were used to parameterize a closed cohort-level partitioned survival model that predicted time-to-event for key trial endpoints (kidney failure, all-cause mortality, sustained decline in kidney function and hospitalization for heart failure). Data were pooled with a subpopulation of the Dapagliflozin Effect on Cardiovascular Events – Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) trial to create a combined CKD population spanning a range of CKD stages; a parallel survival analysis was conducted in this population.

Results

In the DAPA-CKD and pooled CKD populations, treatment with dapagliflozin delayed time to first event for kidney failure, all-cause mortality, sustained decline in kidney function and hospitalization for heart failure. Attenuation of CKD progression was predicted to slow the time to kidney failure by 6.6 years [dapagliflozin: 25.2, 95% confidence interval (CI) 19.0–31.5; standard therapy: 18.5, 95% CI 14.7–23.4] in the DAPA-CKD population. A similar result was observed in the pooled CKD population with an estimated delay of 6.3 years (dapagliflozin: 36.0, 95% CI 31.9–38.3; standard therapy: 29.6, 95% CI 25.5–34.7).

Conclusion

Treatment with dapagliflozin over a lifetime time horizon may considerably delay the mean time to adverse clinical outcomes for patients who would go on to experience them, including those at modest risk of progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesRenal Insufficiency, ChronicDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsDisease ProgressionHumansFemaleMaleMiddle AgedAgedFollow-Up StudiesGlomerular Filtration RatePrognosis

Stichwörter der Autor:innen

SGLT2 inhibitorchronic kidney diseasechronic renal failurediabetic kidney diseasemortality

Substanzen

dapagliflozinBenzhydryl CompoundsGlucosidesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Health Economics and Outcomes Research Ltd, Cardiff, UK.
  • Health Economic and Payer Evidence, AstraZeneca, Cambridge, UK.
  • Late-Stage Development, Cardiovascular, Renal, and Metabolism, AstraZeneca, Gothenburg, Sweden.
  • Global Medical Affairs, AstraZeneca, Gaithersburg, USA.
  • Medical & Payer Evidence Statistics, AstraZeneca, Gothenburg, Sweden.
  • Global Commercial Integration, AstraZeneca, Cambridge, UK.

ORCID-Profile: Peter Rossing, Hiddo J L Heerspink

Förderung

  • AstraZeneca

Zitieren

APA

McEwan, P., Gabb, P. D., Davis, J. A., Garcia Sanchez, J. J., Sjöström, C. D., Barone, S., Kashioulis, P., Ouwens, M., Cassimaty, S., Correa-Rotter, R., Rossing, P., Wheeler, D. C., & Heerspink, H. J. L. (2024). The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfae106

Vancouver

McEwan P, Gabb PD, Davis JA, Garcia Sanchez JJ, Sjöström CD, Barone S, et al. The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis. Nephrology Dialysis Transplantation. 2024. doi:10.1093/ndt/gfae106

BibTeX
@article{McEwan2024,
  author = {McEwan, Phil and Gabb, Peter D and Davis, Jason A and Garcia Sanchez, Juan Jose and Sjöström, C David and Barone, Salvatore and Kashioulis, Pavlos and Ouwens, Mario and Cassimaty, Syd and Correa-Rotter, Ricardo and Rossing, Peter and Wheeler, David C and Heerspink, Hiddo J L},
  title = {The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis},
  journal = {Nephrology Dialysis Transplantation},
  year = {2024},
  doi = {10.1093/ndt/gfae106}
}
Kostenlos starten →